Magnolia Neurosciences is developing a new class of neuroprotective therapies that target specific components of programmed cell death to preserve brain tissue. The company’s programs are built on discoveries from The University of Texas MD Anderson Cancer Center and the Neurodegeneration Consortium. Preclinical data cited in the articles show that blocking these pathways preserves neurons and leads to enhanced memory in animal models. Magnolia aims to develop potent, highly selective neuroprotective therapies with compelling preclinical pharmacologic profiles and to obtain clinical proof of concept rapidly. The company was launched with a $31 million Series A investment and is positioned to address unmet needs across Alzheimer’s disease, neuronal injury, and other CNS conditions. Its offices are located in the Alexandria Center for Life Science in New York City.

Total raised

$31M

Funding rounds

1

Latest round

Series A

Latest activity

Aug 2018